Company Overview of Xigen SA
Xigen SA, a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases in the areas of inflammation, central nervous system, oncology, and virology, as well as cancers. Its products include XG-102, a non-ATP competitive peptide based inhibitor of c-jun N-terminal kinase (JNK) that is an intracellular therapeutic target; and XG-102 (AM-111) for acute sensorineural hearing loss. The company was founded in 2002 and is based in Lausanne, Switzerland.
17, rue des Terreaux
Founded in 2002
41 21 321 10 80
41 21 321 10 81
Key Executives for Xigen SA
Similar Private Companies By Industry
|Biogen Idec Switzerland AG||Europe|
|Cell Culture Technologies LLC||Europe|
|Glaxo Institute for Molecular Biology||Europe|
|SMtec Biovision Holding AG||Europe|
|Rapid Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Xigen SA, please visit www.xigenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.